| Similar Articles |
|---|
 |
Bio-IT World
November 19, 2004
Malorye A. Branca |
Engines of Discovery It's what every biotech startup promises but few deliver, a turbo-charged discovery engine. Every now and then, however, a new company with fresh ideas starts hitting home runs.   |
Bio-IT World
June 15, 2003
Barbara Depompa |
Southwest Region Texas: Bioscience with a Space Spin... New Mexico: Building a Bioinformatics Niche... Arizona: Focus on Cancer and Neurological Therapy... Southern California: Deep Biotech Roots Grow Many Branches... Northern California: 'Can You Afford To Be Elsewhere?'... |
The Motley Fool
December 14, 2010
Travis Hoium |
Lexicon Pharmaceuticals Shares Plunged: What You Need to Know Lexicon Pharmaceuticals shares fell as much as 14% in intraday trading on disappointing results of its rheumatoid arthritis drug test. |
Fast Company
November 2009
David H. Freedman |
The Gene Bubble: Why We Still Aren't Disease-Free When the human genome was first sequenced nearly a decade ago, the world lit up with talk about how new gene-specific drugs would help us cheat death. Well, the verdict is in: Keep eating those greens. |
The Motley Fool
January 7, 2011
Brian Orelli |
A Biotech Roller Coaster Lexicon is back on the upswing. |
The Motley Fool
February 9, 2007
Brian Lawler |
Picking Up the Pace at Seattle Genetics The cash situation shows the shares of this drug development company could be appealing. |
The Motley Fool
October 18, 2010
Travis Hoium |
Lexicon Pharmaceuticals Shares Popped: What You Need to Know Lexicon Pharmaceuticals shares jumped 10% in early trading Monday on unusually high trading. |
The Motley Fool
December 15, 2010
Brian Orelli |
Beautiful Efficacy, Wrong Pill Lexicon Pharmaceuticals presented beautiful data showing a pill it gave rheumatoid arthritis patients decreased symptoms in 49% of patients. Unfortunately, the pill was a dummy pill with no active ingredient. |
